Advertisement DiaGenic wins NOK7.8m grant to develop blood based diagnostics - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

DiaGenic wins NOK7.8m grant to develop blood based diagnostics

DiaGenic has received NOK7.8m from the Norwegian Research Council`s BIA funds for the development of blood based diagnostic tests to detect Alzheimer's disease.

The Research Council of Norway announced the grant for the project, Blood microRNAs for the early diagnosis of Alzheimer’s disease, which is conditional upon signature by the parties.

DiaGenic CEO Henrik Lund said Norwegian Research Council has in the past contributed with significant funding for DiaGenic’s development of diagnostic tests.

"This new grant for development of blood based diagnostics for early Alzheimer’s disease represents an important financial contribution," Lund added.

DiaGenic’s biobank and the HUNT Biosciences biobank will supply the clinical samples, the company said.